Epigallocatechin Gallate: meta-analysis of COVID-19 studies

All studies   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 38% 1 114 Improvement, Studies, Patients Relative Risk RCTs 38% 1 114 Late 38% 1 114 Epigallocatechin Gallate for COVID-19 c19early.org January 2026 Favorsepigallocatechin gallate Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Zhu (RCT) 38% 0.62 [0.50-0.90] no improv. 30/76 23/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.015 Late treatment 38% 0.62 [0.50-0.90] 30/76 23/38 38% lower risk All studies 38% 0.62 [0.50-0.90] 30/76 23/38 38% lower risk 1 epigallocatechin gallate COVID-19 study c19early.org January 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.015 Effect extraction pre-specified(most serious outcome) Favors epigallocatechin gallate Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Zhu (RCT) 38% 0.62 [0.50-0.90] no improv. 30/76 23/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.015 Late treatment 38% 0.62 [0.50-0.90] 30/76 23/38 38% lower risk All studies 38% 0.62 [0.50-0.90] 30/76 23/38 38% lower risk 1 epigallocatechin gallate COVID-19 Randomized Controlled Trial c19early.org January 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.015 Effect extraction pre-specified(most serious outcome) Favors epigallocatechin gallate Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Zhu (RCT) 38% 0.62 [0.50-0.90] no improv. 30/76 23/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.015 Late treatment 38% 0.62 [0.50-0.90] 30/76 23/38 38% lower risk All studies 38% 0.62 [0.50-0.90] 30/76 23/38 38% lower risk 1 epigallocatechin gallate COVID-19 peer reviewed studies c19early.org January 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.015 Effect extraction pre-specified(most serious outcome) Favors epigallocatechin gallate Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Zhu (RCT) 38% 0.62 [0.50-0.90] no improv. 30/76 23/38 Improvement, RR [CI] Treatment Control Epigallocatechin gallate COVID-19 outcomes c19early.org January 2026 Favors epigallocatechin gallate Favors control